Want to see PHIO full AI Analyst Report?

Phio Pharmaceuticals (PHIO) Price & Analysis

656 Followers

PHIO Stock Chart & Stats

$1.19

-$0.09(-4.97%)

At close: Jan 08 4:00 PM EST

$1.19

-$0.09(-4.97%)

Day’s Range― - ―

52-Week Range$0.81 - $4.19

Previous CloseN/A

Volume62.29K

Average Volume (3M)137.46K

Market Cap

$11.27M

Enterprise Value-$4.48M

Total Cash (Recent Filing)$17.03M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.37

Next Earnings

Aug 06, 2026

EPS Estimate

-0.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.43

Shares Outstanding11,617,250

10 Day Avg. Volume82,534

30 Day Avg. Volume137,459

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.31

Price to Sales (P/S)0.00

P/FCF Ratio-0.79

Enterprise Value/Market Cap-0.40

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit4.17

Enterprise Value/Ebitda0.41

Forecast

1Y Price Target

$14.00

Price Target Upside1076.47% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.21

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 1b data showed a high rate of pathologic responses in treated cutaneous skin cancer patients, including multiple complete clearances, indicating meaningful anti-tumor activity for PH-762.

Regulatory PathwayPlanned engagement with the FDA to define next clinical steps could clarify the development pathway and improve commercial visibility for the INTASYL delivery platform.

Safety ProfilePH-762 exhibited a consistent safety profile with no dose-limiting toxicities or serious treatment-related adverse events reported, supporting continued clinical evaluation.

Bears Say

Data MaturityCurrent findings are preliminary and require additional data to confirm durability of responses and applicability across broader patient populations.

Development RiskPH-762 remains in early clinical development, which creates substantial uncertainty around long-term outcomes and the likelihood of regulatory approval.

Phio Pharmaceuticals News

PHIO Earnings this Week: How Will it Perform?

Phio Pharmaceuticals (PHIO) is scheduled to report 1st quarter earnings on 05/07/2026. Regarding Q1 estimates, Wall Street analysts...

2M ago

PHIO

Phio Pharmaceuticals Establishes New At-the-Market Equity Program

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On April 8, 2026, Phio Pharmaceuticals entered into an...

3M ago

PHIO

Phio Pharmaceuticals Secures cGMP Manufacturing for Clinical Supply

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On March 30, 2026, Phio Pharmaceuticals announced it had...

3M ago

PHIO

Buy Rating on PHIO: Strong Early PH-762 Clinical Data and Solid Cash Runway Support Upside Potential

Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, retaining the price target of...

4M ago

PHIO

Phio Pharmaceuticals Boosts CEO Severance and Incentive Compensation

The latest update is out from Phio Pharmaceuticals ( ($PHIO) ). On February 17, 2026, Phio Pharmaceuticals Corp....

4M ago

PHIO

Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results

Phio Pharmaceuticals ( ($PHIO) ) has shared an announcement. On February 10, 2026, Phio Pharmaceuticals reported that an...

5M ago

PHIO

Buy Rating on Phio Pharmaceuticals: Early PH-762 Efficacy, Clean Safety Profile, and Solid Cash Runway Support Favorable Risk–Reward

Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, retaining the price target of...

5M ago

PHIO

Phio Reports Positive Phase 1b PH-762 Skin Cancer Data

The latest announcement is out from Phio Pharmaceuticals ( ($PHIO) ). On January 20, 2026, Phio Pharmaceuticals reported...

5M ago

PHIO

Phio Advances PH-762 With FDA-Backed Toxicology Study

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, 2025, Phio Pharmaceuticals announced that the...

6M ago

PHIO

Phio Pharmaceuticals Completes Enrollment for PH-762 Trial

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On November 25, 2025, Phio Pharmaceuticals announced the completion...

7M ago

PHIO

Phio Pharmaceuticals files to sell 11.76M shares of common stock for holders

The company will not receive any of the proceeds from the sale by the selling stockholders of the...

7M ago

PHIO

Phio Pharmaceuticals files to sell 1.93M shares of common stock for holders

06:08 EDT Phio Pharmaceuticals (PHIO) files to sell 1.93M shares of common stock for holders Published first on...

11M ago

PHIO

Phio Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Phio Pharmaceuticals (PHIO) with a Buy rating and $14 price target Phio’s lead...

1y ago

PHIO

Phio Pharmaceuticals files to sell 5.93M shares of common stock for holders

16:41 EST Phio Pharmaceuticals (PHIO) files to sell 5.93M shares of common stock for holders Published first on...

1y ago

PHIO

PHIO FAQ

What was Phio Pharmaceuticals’s price range in the past 12 months?

Phio Pharmaceuticals lowest stock price was $0.81 and its highest was $4.19 in the past 12 months.

What is Phio Pharmaceuticals’s market cap?

Phio Pharmaceuticals’s market cap is $11.27M.

When is Phio Pharmaceuticals’s upcoming earnings report date?

Phio Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 37 days.

How were Phio Pharmaceuticals’s earnings last quarter?

Phio Pharmaceuticals released its earnings results on May 07, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.235 by -$0.105.

Is Phio Pharmaceuticals overvalued?

According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Phio Pharmaceuticals pay dividends?

Phio Pharmaceuticals does not currently pay dividends.

What is Phio Pharmaceuticals’s EPS estimate?

Phio Pharmaceuticals’s EPS estimate is -0.36.

How many shares outstanding does Phio Pharmaceuticals have?

Phio Pharmaceuticals has 11,617,250 shares outstanding.

What happened to Phio Pharmaceuticals’s price movement after its last earnings report?

Phio Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.235. Following the earnings report the stock price went down -0.87%.

Which hedge fund is a major shareholder of Phio Pharmaceuticals?

Currently, no hedge funds are holding shares in PHIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Phio Pharmaceuticals

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Phio Pharmaceuticals (PHIO) Earnings & Revenues

Historic Earnings Reports

PHIO Stock 12 Month Forecast

Average Price Target

$14.00

▲(1076.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3,7,11,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,2.12,3.1100000000000003,4.1,5.09,6.08,7.07,8.06,9.05,10.04,11.030000000000001,12.02,13.010000000000002,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,2.12,3.1100000000000003,4.1,5.09,6.08,7.07,8.06,9.05,10.04,11.030000000000001,12.02,13.010000000000002,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,2.12,3.1100000000000003,4.1,5.09,6.08,7.07,8.06,9.05,10.04,11.030000000000001,12.02,13.010000000000002,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.987,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >